[{"id":"8b6df141-7b64-4f9b-89f3-9e3e39a78d70","acronym":"NCI-2017-00831","url":"https://clinicaltrials.gov/study/NCT03066206","created_at":"2021-01-17T17:10:50.278Z","updated_at":"2024-07-02T16:35:01.092Z","phase":"Phase 2","brief_title":"Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC","source_id_and_acronym":"NCT03066206 - NCI-2017-00831","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pozenveo (poziotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"},{"id":"93f98008-2763-4eb8-b3d9-f6477ef24b99","acronym":"FURMO-002","url":"https://clinicaltrials.gov/study/NCT05364073","created_at":"2022-05-06T18:55:07.280Z","updated_at":"2024-07-02T16:35:02.618Z","phase":"Phase 1","brief_title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","source_id_and_acronym":"NCT05364073 - FURMO-002","lead_sponsor":"ArriVent BioPharma, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-20"},{"id":"1e5fae6d-b76f-41f6-b24b-b33b5b08e9ca","acronym":"ORIC-114-01","url":"https://clinicaltrials.gov/study/NCT05315700","created_at":"2022-04-07T13:56:31.880Z","updated_at":"2024-07-02T16:35:04.393Z","phase":"Phase 1/2","brief_title":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","source_id_and_acronym":"NCT05315700 - ORIC-114-01","lead_sponsor":"ORIC Pharmaceuticals","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • HER-2 amplification • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • HER-2 amplification • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • enozertinib (ORIC-114)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-05-10"},{"id":"0e951a08-185b-43b0-abfd-bacd8cecb2d9","acronym":"PINNACLE","url":"https://clinicaltrials.gov/study/NCT05378763","created_at":"2022-05-18T13:00:48.132Z","updated_at":"2024-07-02T16:35:19.182Z","phase":"Phase 3","brief_title":"A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations","source_id_and_acronym":"NCT05378763 - PINNACLE","lead_sponsor":"Spectrum Pharmaceuticals, Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Pozenveo (poziotinib)"],"overall_status":"Suspended","enrollment":" Enrollment 268","initiation":"Initiation: 05/12/2022","start_date":" 05/12/2022","primary_txt":" Primary completion: 12/25/2027","primary_completion_date":" 12/25/2027","study_txt":" Completion: 12/25/2028","study_completion_date":" 12/25/2028","last_update_posted":"2024-02-15"},{"id":"5099b846-9a06-490a-87e5-9edae2154cd9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05745740","created_at":"2023-02-27T15:01:09.062Z","updated_at":"2024-07-02T16:35:28.037Z","phase":"Phase 1/2","brief_title":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","source_id_and_acronym":"NCT05745740","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation • HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • Aidixi (disitamab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-27"},{"id":"24a9df1f-6dbc-4a16-8c54-13431c420129","acronym":"EXCLAIM","url":"https://clinicaltrials.gov/study/NCT02716116","created_at":"2021-01-17T17:11:37.814Z","updated_at":"2024-07-02T16:35:32.901Z","phase":"Phase 1/2","brief_title":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02716116 - EXCLAIM","lead_sponsor":"Takeda","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Exkivity (mobocertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 334","initiation":"Initiation: 06/16/2016","start_date":" 06/16/2016","primary_txt":" Primary completion: 03/28/2025","primary_completion_date":" 03/28/2025","study_txt":" Completion: 03/28/2025","study_completion_date":" 03/28/2025","last_update_posted":"2023-10-18"},{"id":"ea7b0831-aa27-4710-8ad0-16bc4a75633a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06067776","created_at":"2023-10-05T16:11:05.700Z","updated_at":"2024-07-02T16:35:34.583Z","phase":"Phase 1","brief_title":"Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer","source_id_and_acronym":"NCT06067776","lead_sponsor":"Jonathan Riess","biomarkers":" HER-2 • BRAF • ALK • MET • RET","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation","tags":["HER-2 • BRAF • ALK • MET • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tagrisso (osimertinib) • Tukysa (tucatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2023-10-05"},{"id":"1978da50-39bd-4ed1-bae5-634d56f98b7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800340","created_at":"2023-04-05T14:03:39.507Z","updated_at":"2024-07-02T16:35:51.386Z","phase":"Phase 2","brief_title":"Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC","source_id_and_acronym":"NCT05800340","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" HER-2 • PD-L1 • BRAF • MET • RET","pipe":" | ","alterations":" BRAF V600E • HER-2 amplification • HER-2 mutation • MET amplification • RET fusion • MET exon 14 mutation • MET mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2 • PD-L1 • BRAF • MET • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • HER-2 amplification • HER-2 mutation • MET amplification • RET fusion • MET exon 14 mutation • MET mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/04/2023","start_date":" 04/04/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-04-05"},{"id":"1ba66b3e-54fe-4d02-972d-169ab5065f83","acronym":"","url":"https://clinicaltrials.gov/study/NCT05435274","created_at":"2022-06-28T15:54:10.303Z","updated_at":"2024-07-02T16:36:08.178Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05435274","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HS-10376"],"overall_status":"Recruiting","enrollment":" Enrollment 380","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 10/07/2024","primary_completion_date":" 10/07/2024","study_txt":" Completion: 10/07/2025","study_completion_date":" 10/07/2025","last_update_posted":"2022-06-28"},{"id":"c52db608-0147-4e7b-a4a9-1aa8cea334b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04382300","created_at":"2021-01-18T21:09:42.983Z","updated_at":"2024-07-02T16:36:35.432Z","phase":"Phase 2","brief_title":"Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions","source_id_and_acronym":"NCT04382300","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • thalidomide"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/30/2020","start_date":" 06/30/2020","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2021-01-28"},{"id":"49a4a0b5-0da7-4007-b016-2998d04ed0a0","acronym":"REFLECT","url":"https://clinicaltrials.gov/study/NCT04031898","created_at":"2021-01-18T19:47:14.893Z","updated_at":"2024-07-02T16:36:36.923Z","phase":"","brief_title":"Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)","source_id_and_acronym":"NCT04031898 - REFLECT","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ALK • TP53 • MET","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • HER-2 amplification • EGFR exon 19 deletion • MET amplification • EGFR T790M • MET expression • ALK rearrangement + MET amplification • HER-2 exon 23 mutation","tags":["HER-2 • ALK • TP53 • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • HER-2 amplification • EGFR exon 19 deletion • MET amplification • EGFR T790M • MET expression • ALK rearrangement + MET amplification • HER-2 exon 23 mutation"],"overall_status":"Completed","enrollment":" Enrollment 896","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2020-12-23"},{"id":"3eb241b5-7c82-4eb0-b29d-fa3a40d5f558","acronym":"","url":"https://clinicaltrials.gov/study/NCT04063462","created_at":"2021-01-18T19:54:43.222Z","updated_at":"2024-07-02T16:36:56.727Z","phase":"Phase 2","brief_title":"Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation","source_id_and_acronym":"NCT04063462","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2019-08-21"},{"id":"c9f77032-3d78-42e6-a36e-d332ab921330","acronym":"","url":"https://clinicaltrials.gov/study/NCT02827357","created_at":"2021-01-18T13:51:45.339Z","updated_at":"2024-07-02T16:37:30.750Z","phase":"","brief_title":"Responses to Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 Mutation","source_id_and_acronym":"NCT02827357","lead_sponsor":"University Hospital, Toulouse","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 09/01/2015","study_completion_date":" 09/01/2015","last_update_posted":"2016-07-11"}]